With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...

Genetic, biochemical and structural studies have implicated Argonaute proteins as the catalytic core of the RNAi effector complex, RISC. Here we show that recombinant, human Argonaute2 can combine ...

A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

SHANGHAI and SANTA BARBARA, Calif., /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, ...

AstraZeneca is set to pay Silence Therapeutics $60 million (€55 million) to work on siRNA therapies against cardiovascular, renal, metabolic and respiratory disease targets. The upfront cash fee is ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Transfecting siRNA with a high efficiency won’t be a challenge for you anymore thanks to these tips. siRNA transfection is a powerful tool to understand underlying mechanisms in gene regulation and ...

“The copious patentable aspects of a therapeutically efficacious siRNA delivery formulation imply intense patenting activity in the years to come, along with market exclusivity that can be extended ...